Search filters

List of works by Kim A. Papp

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

scientific article published in October 2011

A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis.

scientific article

A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients.

scientific article published in November 2009

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

scientific article published on 02 September 2020

A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution

scientific article published on 30 March 2016

A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.

scientific article

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

scientific article

A Review of Psoriasis, Therapies, and Suicide.

scientific article published on 5 May 2016

A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults

scientific article

A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence

scientific article

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

scientific article published on 01 June 2005

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

scientific article published on 30 December 2019

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

scientific article published on 8 January 2011

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

scientific article published on 21 February 2015

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis

scientific article published on 20 October 2011

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

scientific article published on 23 February 2016

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

scientific article published on 6 September 2006

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

scientific article published on July 2013

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

scientific article published on 22 January 2016

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

scientific article published on 01 December 2002

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

scientific article

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

scientific article published on 01 March 2010

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

scientific article published on 23 January 2006

AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis

scientific article published on 26 September 2019

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.

scientific article published on 7 November 2015

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

scientific article published in February 2011

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.

scientific article published on 6 October 2017

Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.

scientific article published on September 2009

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

scientific article

An Open Letter to Health Canada

scientific article published in May 2017

An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12

scientific article published on 23 September 2019

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

scientific article published on December 2005

Analytical approaches to reporting long-term clinical trial data

scientific article published on 04 June 2008

Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

scientific article

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

scientific article

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM

scientific article published on July 2015

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

scientific article published on 04 July 2019

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

scientific article published on 17 September 2010

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

scientific article published on 01 March 2012

Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group

scientific article published on 01 January 2000

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

scientific article published on 03 February 2011

Canadian Guidelines for the Management of Plaque Psoriasis: Overview ⬇️

scientific article published on 01 July 2011

Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

scientific article published on April 2011

Clinical Trial and Registry Data.

scientific article

Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis.

scientific article published on October 2010

Clinical meaningfulness of complete skin clearance in psoriasis.

scientific article

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

scientific article

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis

scientific article published on 28 July 2017

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis.

scientific article published in May 2010

Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"

scientific article published on 02 August 2017

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.

scientific article published on 18 August 2017

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

scientific article published in The Lancet

Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body.

scientific article published on 23 August 2010

Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis

scientific article published on 10 October 2018

Consensus guidelines for the management of plaque psoriasis.

scientific article

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

scientific article published on 11 February 2017

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

scientific article published on 13 July 2020

Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis.

scientific article published on 27 October 2011

Diagnosis and Management of Conjunctivitis for the Dermatologist.

scientific article published in November 2017

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept.

scientific article published on 7 March 2013

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

scientific article published on 22 May 2013

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

scientific article published on 30 March 2016

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

scientific article

Efalizumab for the treatment of psoriatic arthritis

scientific article published on 01 March 2007

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

scientific article published on 01 April 2006

Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.

scientific article published in December 2004

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

scientific article

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

scientific article published on 04 October 2007

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

scientific article published on 8 May 2015

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

scientific article published on 21 March 2020

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

scientific article published on 10 January 2017

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

scientific article published on 4 May 2017

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study

scientific article published on 25 October 2011

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study ⬇️

scientific article published on October 3, 2012

Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.

scientific article published on 29 December 2014

Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P).

scientific article published on 6 February 2018

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

scientific article

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa

scientific article published on 29 December 2016

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study

scientific article published on 17 April 2019

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

scientific article published on 18 January 2013

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

scientific article published on 05 September 2019

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

scientific article

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

scientific article published on 13 June 2013

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

scientific article

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

scientific article

Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

scientific article published in June 2005

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

scientific article published on 01 April 2008

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

scientific article published on 29 June 2012

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation

scientific article

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

scientific article published on 01 December 2019

Epidemiology and quality of life of patients with psoriasis in Chile ⬇️

scientific article published on June 12, 2011

Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population.

scientific article

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

scientific article

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

scientific article published on January 2006

Etanercept in psoriasis

scientific article published in October 2004

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

scientific article published on 11 September 2017

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

scientific article published on 19 October 2015

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

scientific article

Evaluation of efalizumab using safe psoriasis control

scientific article

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

scientific article published on 8 May 2015

Examining the risk of cardiovascular disease in patients with psoriasis: a critical review.

scientific article published on March 2013

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.

scientific article published on 16 July 2015

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody

scientific article published on 02 November 2018

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.

scientific article

Impact of Previous Biologic Use on Efficacy and Safety of Brodalumab and Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analysis of AMAGINE-2 and AMAGINE-3.

scientific article published on 28 February 2018

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

scientific article published in October 2010

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.

scientific article

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

scientific article published on 21 January 2015

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

scientific article published on 10 May 2013

Infections from 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis

scientific article published on 10 June 2017

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

scientific article published on 01 October 2005

Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.

scientific article

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

scientific article published in April 2001

Ixekizumab for psoriasis--Authors' reply

scientific article published on 15 January 2016

Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis

scientific article

Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

scientific article

Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot

scientific article published on 14 October 2021

Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series

scientific article published on 7 May 2015

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL

scientific article published on 14 July 2011

Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis

scientific article published on 01 November 2008

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years ⬇️

scientific article published on April 1, 2012

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

scientific article

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

scientific article published on 4 May 2017

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.

scientific article published on 16 March 2012

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).

scientific article published on 14 April 2017

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

scientific article published on 5 October 2011

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

scientific article published on 01 April 2013

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition.

scientific article

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.

scientific article published on 24 August 2017

Management of egfr tki-induced dermatologic adverse events.

scientific article

Managing cardiovascular risk in patients with chronic inflammatory diseases.

scientific article published on 14 January 2012

Monitoring biologics for the treatment of psoriasis

scientific article published on September 2008

Monitoring patients treated with efalizumab or alefacept.

scientific article published on 28 July 2009

OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.

scientific article

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.

scientific article published on 14 February 2017

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study

scientific article published on 01 October 2012

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.

scientific article published on 10 August 2017

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial

scientific article published on 01 March 2006

Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.

scientific article published in December 2009

Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices

scientific article

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

scientific article published on 11 September 2018

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

scientific article published on October 2015

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

scientific article published on 8 June 2016

Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.

scientific article published on 27 May 2017

Potential future therapies for psoriasis.

scientific article

Practical Management of Patients with Atopic Dermatitis on Dupilumab

scientific article published on 11 September 2021

Predictors of Topical Use in Psoriasis Patients in the REFINE Study

scientific article published on September 2015

Preparing for subsequent entry biologics in dermatology and rheumatology in Canada

scientific article published in September 2013

Psoriasis care: new and emerging pharmacologic trends

scientific article published on May 2010

Psoriasis: consensus on topical therapies.

scientific article published on 13 December 2007

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

scientific article published on 3 October 2017

Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea

scientific article published on 13 May 2002

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.

scientific article published in May 2018

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).

scientific article published on August 2017

Relapse, rebound, and psoriasis adverse events: an advisory group report.

scientific article

Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients

scientific article published on April 2007

Review of Systemic Treatment Options for Adult Atopic Dermatitis.

scientific article published on 15 September 2016

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

scientific article

Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment

scientific article published on 01 December 2005

Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

scientific article published in October 2017

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

scientific article published on 11 October 2014

Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

scientific article

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

scientific article published on 01 May 2006

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

scientific article

Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

scientific article published on January 2008

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

scientific article published on 01 May 2019

Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies

scientific article published on 01 July 2010

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

scientific article

Scalp psoriasis: a review of current topical treatment options.

scientific article published on October 2007

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

scientific article

Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.

scientific article published on 13 February 2018

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

scientific article

Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial

scientific article published on 13 July 2010

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

scientific article

Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial

scientific article published on 15 December 2019

Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study

scientific article published on 25 July 2019

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study

scientific article published on 01 April 2011

Systemic gold therapy

scientific article published on October 1991

The AWARE study: methodology and baseline characteristics.

scientific article

The incidence of cancer associated with the treatment of rheumatoid arthritis

scientific article published on 01 December 1999

The long-term efficacy and safety of new biological therapies for psoriasis

scientific article

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials

scientific article published on October 2011

The psychosocial impact of hidradenitis suppurativa.

scientific article

The safety of etanercept for the treatment of plaque psoriasis.

scientific article published in June 2007

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

scientific article published on 01 November 2001

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

scientific article

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.

scientific article published on 17 July 2017

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

scientific article

Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations ⬇️

scientific article published on November 1, 2011

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

scientific article published on 16 July 2016

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice

scientific article published on 01 April 2017

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.

scientific article

Trial of Roflumilast Cream for Chronic Plaque Psoriasis

scientific article published on 01 July 2020

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

scientific article published on August 2016

Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments.

scientific article published on May 2013

Update on alefacept safety

scientific article published on 01 December 2009

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

scientific article published on 9 November 2009

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.

scientific article published in January 2004

Paulina is supported by:

About Paulina

Help